Form 4: ANAB Director John Orwin Receives Equity Grants

ANAPTYSBIO, INC. Director John A. Orwin was granted 8,250 stock options and 6,000 restricted stock units on January 6, 2026.

Summary

• Director John A. Orwin of ANAPTYSBIO, INC. received equity grants on January 6, 2026.
• The grants include 8,250 stock options with an exercise price of $43.91.
• These stock options will vest monthly at a rate of 1/12 of the total shares, starting February 6, 2026, and expire on January 5, 2036.
• Additionally, 6,000 Restricted Stock Units (RSUs) were granted.
• The RSUs will vest 100% on the date of the Issuer's 2027 annual meeting of shareholders.
• All grants are subject to Mr. Orwin's continued provision of service to the Issuer.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports routine equity grants to a director, which is a positive for aligning management incentives but has a neutral to slightly negative impact on immediate share price due to potential future dilution. The pre-planned nature (10b5-1) makes it an expected event.

Positives

• Director John A. Orwin received a grant of 8,250 stock options, aligning his interests with long-term shareholder value.
• An additional grant of 6,000 Restricted Stock Units (RSUs) further incentivizes the director's continued service and performance.
• The vesting schedules for both options and RSUs promote long-term commitment from the director.

Negatives

• The grants represent potential future dilution for existing shareholders if the options are exercised and RSUs settle into common stock.

Risks

• The vesting of stock options and restricted stock units is contingent upon the reporting person's continued provision of service to the Issuer, meaning the awards could be forfeited if service ceases.
• The value of the stock options is dependent on the future market price of ANAPTYSBIO, INC. common stock exceeding the exercise price of $43.91.

Future Outlook

The equity grants are structured with vesting schedules extending into 2027 and 2036, indicating a long-term incentive strategy for the director's continued service and alignment with future company performance.

Industry Context

Equity grants to directors are a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to align leadership interests with long-term shareholder value and retain talent in a competitive sector.

Related Party Transactions

• The grant of 8,250 stock options and 6,000 Restricted Stock Units to Director John A. Orwin constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options and settlement of RSUs, but also benefit from increased alignment of director's interests with long-term company performance.
• Director (John A. Orwin): Receives significant equity compensation, incentivizing continued service and performance.

Next Steps

• The stock options will begin vesting monthly starting February 6, 2026.
• The Restricted Stock Units (RSUs) are scheduled to vest 100% on the date of the Issuer's 2027 annual meeting of shareholders.

Key Dates

Recommendation

This Form 4 reports routine equity compensation for a director, which is a standard practice for aligning management incentives with shareholder interests. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The grants are expected and part of a pre-planned compensation structure.

Keywords

ANAPTYSBIO, ANAB, Form 4, stock options, restricted stock units, equity grant, director compensation, insider transaction, John Orwin, Rule 10b5-1